Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NR4A2 | P43354 | 2/20 | 0.51 |
| ▸ | ACHE | P22303 | 6/20 | 0.47 |
| ▸ | BCHE | P06276 | 4/20 | 0.47 |
| ▸ | GRIN1 | Q05586 | 4/20 | 0.47 |
| ▸ | GRIN2A | Q12879 | 4/20 | 0.47 |
| ▸ | MAP4K4 | O95819 | 1/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.45 |
| ▸ | MAP3K14 | Q99558 | 2/20 | 0.43 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.42 |
| ▸ | NPFFR1 | Q9GZQ6 | 1/20 | 0.42 |
| ▸ | NPFFR2 | Q9Y5X5 | 1/20 | 0.42 |
| ▸ | HSP90AB1 | P08238 | 1/20 | 0.42 |
| ▸ | PARP1 | P09874 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18658904 | 0.81 | NR4A2 (0.59) | NR4A2ACHEBCHEGRIN1GRIN2A | |
| SCHEMBL439464 | 0.81 | NR4A2 (0.55) | NR4A2ACHEBCHEGRIN1GRIN2A | |
| SCHEMBL30155016 | 0.81 | NR4A2 (0.59) | NR4A2ACHEBCHEGRIN1GRIN2A | |
| SCHEMBL437551 | 0.79 | NR4A2 (0.51) | NR4A2ACHEBCHEGRIN1GRIN2A | |
| SCHEMBL27916573 | 0.75 | MAP4K4 (0.52) | NR4A2ACHEBCHEGRIN1GRIN2A | |
| SCHEMBL2519868 | 0.74 | ALDH1A1 (0.54) | NR4A2ALDH1A1MAP3K14CYP3A4 | |
| SCHEMBL17278415 | 0.73 | ALDH1A1 (0.41) | NR4A2MAP4K4ALDH1A1CYP3A4NPFFR1 | |
| SCHEMBL440411 | 0.73 | HAVCR2 (0.52) | NR4A2ACHEBCHEGRIN1GRIN2A | |
| SCHEMBL2519637 | 0.73 | KDM4E (0.50) | ACHEBCHEGRIN1GRIN2AALDH1A1 | |
| SCHEMBL28458986 | 0.73 | NR4A2 (0.58) | NR4A2ACHEBCHEGRIN1GRIN2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20200246345-A1 | ALDEHYDE CONJUGATES AND USES THEREOF | ALDEYRA THERAPEUTICS, INC. | 2020-08-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200246345-A1 | ALDEHYDE CONJUGATES AND USES THEREOF | ALDH1A2, AOX1, ALDH2 | NR4A2 3506/4885ACHE 607/4885BCHE 237/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.